Prof. Stefano Fiorucci invito dall' Accademia Russa delle Scienze conferenza a San Pietroburgo su recettori nucleari e recettori per acid biliari utilizzati nel trattamento del diabete ed obesità e loro applicazione clinica
Review that illustartes the link between bile acids and non steroideal anti-inflmmatory drugs and aspirin in the small intestine.
Discovery of the activity of liquorice on FXR
These are intracellular (cytoplasmic or
nuclear) soluble proteins which respond to
lipid soluble chemical messengers that penetrate
the cell (Fig. 4.10). The receptor protein (specific for each hormone/regulator) is inherently
capable of binding to specific genes, but its
attached proteins HSP-90 and may be some
others prevent it from adopting the configuration needed for binding to DNA. When the
hormone binds near the carboxy terminus of
the receptor, the restricting proteins (HSP-90,
etc.) are released, the receptor dimerizes and
the DNA binding regulatory segment located
in the middle of the molecule folds into the
functionally active configuration. The liganded
receptor dimer moves to the nucleus and binds
other co-activator/co-repressor proteins which
have a modulatory influence on its capacity to
alter gene function. The whole complex then
attaches to specific DNA sequences (hormone
response elements) of the target genes and
facilitates or represses their expression so
that specific mRNA is synthesized/repressed
on the template of the gene. This mRNA
moves to the ribosomes and directs synthesis
of specific proteins which regulate activity of
the target cells.
All steroidal hormones (glucocorticoids,
mineralocorticoids, androgens, estrogens,
progesterone), thyroxine, vit D and vit A function in this manner. Different steroidal hormones affect different target cells and produce
different effects because each one binds to its
own receptor and directs a unique pattern of
synthesis of specific proteins. The specificity as
to which hormone will be bound is provided
by the hormone binding domain, while that as
to which gene will be activated or repressed
is a function of the DNA binding/N-terminus
domain. Different ligands of the same nuclear
receptor have been found to induce ligand-specific
conformations of the receptor so that different
combinations of co-activators and co-repressors
may be bound in different target tissues, e.g.
selective estrogen receptor modulators (SERMs)
tamoxifen and raloxifene have differing patterns
of action on various estrogenic target organs.
Chimeric receptors have also been produced
which respond to one hormone, but produce
the effects of the other hormone.
This transduction mechanism is the slowest in its time course of action (takes hours)
because the adequate quantity of the effector protein
will have to be produced before the response
occurs. The effects also generally out last
the signal (hormone), because the majority of the
generated effector proteins have slow turnover,
and persist in the body even after the hormone
has been eliminated.
Brian Covello: Diabetes Research ProposalBrian Covello
Brian Covello's diabetes research proposal. Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion.
Essential update: FDA approves subcutaneous albiglutide for management of DM2
The FDA has approved once-weekly injectable albiglutide (Tanzeum), a glucagonlike peptide 1 (GLP-1) receptor agonist, along with diet and exercise for the treatment of type 2 diabetes.[1, 2] This agent may be used either as monotherapy or in combination with metformin, glimepiride, pioglitazone, or insulin.
Albiglutide should not be used for the following[1, 2] :
Patients with type 1 diabetes
Patients with diabetic ketoacidosis
First-line therapy in patients who can’t be managed with diet and exercise
Patients who have a personal or family history of medullary thyroid carcinoma (MTC)
Patients who have multiple endocrine neoplasia syndrome type 2
The most common adverse reactions associated with albiglutide were nausea/diarrhea and injection-site reactions.
There will be a boxed warning on albiglutide’s labeling about thyroid C-cell tumors being observed in rodent studies with this class of drugs; it is currently unknown whether albiglutide causes these tumors in humans, including MTC.[1, 2] Moreover, the FDA is also requiring a number of postmarketing studies, including a pediatric trial; an MTC case registry (≥15 y); and a cardiovascular (CV)-outcomes trial in patients with a baseline high risk of CV disease.
Signs and symptoms
Many patients with type 2 diabetes are asymptomatic. Clinical manifestations include the following:
Classic symptoms: Polyuria, polydipsia, polyphagia, and weight loss
Blurred vision
Lower-extremity paresthesias
Yeast infections (eg, balanitis in men)
See Presentation for more detail.
Diagnosis
Diagnostic criteria by the American Diabetes Association (ADA) include the following[3] :
A fasting plasma glucose (FPG) level of 126 mg/dL (7.0 mmol/L) or higher, or
A 2-hour plasma glucose level of 200 mg/dL (11.1 mmol/L) or higher during a 75-g oral glucose tolerance test (OGTT), or
A random plasma glucose of 200 mg/dL (11.1 mmol/L) or higher in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis
Whether a hemoglobin A1c (HbA1c) level of 6.5% or higher should be a primary diagnostic criterion or an optional criterion remains a point of controversy.
Indications for diabetes screening in asymptomatic adults includes the following[4, 5] :
Sustained blood pressure >135/80 mm Hg
Overweight and 1 or more other risk factors for diabetes (eg, first-degree relative with diabetes, BP >140/90 mm Hg, and HDL < 35 mg/dL and/or triglyceride level >250 mg/dL)
ADA recommends screening at age 45 years in the absence of the above criteria
See Workup for more detail.
Different Therapeutic Aspects of Peroxisomes Proliferator-Activated ReceptorsAI Publications
Peroxisome proliferator-activated receptors (PPARs) was discovered in 1990 belong to the super family of steroid hormone receptors. Three subtypes of PPAR which have been identified so far- PPARα, PPARβ/δ, and PPARγ. Human peroxisome proliferator-activated receptors (hPPARs) were initially recognized as therapeutic targets for the development of drugs to treat metabolic disorders, such as diabetes and dyslipidemia but now they have been used in energy burning, dyslipidemia, diabetes, inflammation, Hepatic steatosis, liver cancer, diabetic neuropathy, atherosclerosis also. These are included in management of NIDDM, macrophage differentiation, adipose differentiation , anti-cancer, inhibition of TH2 cytokine production and rheumatoid arthritis. PPARβ/δ can use to treat Huntington’s disease, fertility, dyslipidemia. The functions of a third PPAR isoform and its potential as a therapeutic target are currently under investigation.
A Thesis Submitted to the College of Medicine and the Committee of Postgraduate Studies of the University of Al-Mustansiriya in Partial Fulfillment of the Requirements for the Degree of Master of Science in Pharmacology
Blocking anti-inflammatory antibodies to histamine/serotonin receptors is a prospective method of medical management of Acute Radiation Disease and can inhibit pro inflammatory cascades and possible damage of internal organs of irradiated mammals.
Il punto sul microbiota e le malattie umane- Covegno scientifico Attività scientifica
Il microbiota e le patologie umane- Perugia 20 aprile 2018- Convegno a Perugia-
Probiotici e trattamento delle patologie umane
Microbiota intestinale e malattie infiammatorie
Review that illustartes the link between bile acids and non steroideal anti-inflmmatory drugs and aspirin in the small intestine.
Discovery of the activity of liquorice on FXR
These are intracellular (cytoplasmic or
nuclear) soluble proteins which respond to
lipid soluble chemical messengers that penetrate
the cell (Fig. 4.10). The receptor protein (specific for each hormone/regulator) is inherently
capable of binding to specific genes, but its
attached proteins HSP-90 and may be some
others prevent it from adopting the configuration needed for binding to DNA. When the
hormone binds near the carboxy terminus of
the receptor, the restricting proteins (HSP-90,
etc.) are released, the receptor dimerizes and
the DNA binding regulatory segment located
in the middle of the molecule folds into the
functionally active configuration. The liganded
receptor dimer moves to the nucleus and binds
other co-activator/co-repressor proteins which
have a modulatory influence on its capacity to
alter gene function. The whole complex then
attaches to specific DNA sequences (hormone
response elements) of the target genes and
facilitates or represses their expression so
that specific mRNA is synthesized/repressed
on the template of the gene. This mRNA
moves to the ribosomes and directs synthesis
of specific proteins which regulate activity of
the target cells.
All steroidal hormones (glucocorticoids,
mineralocorticoids, androgens, estrogens,
progesterone), thyroxine, vit D and vit A function in this manner. Different steroidal hormones affect different target cells and produce
different effects because each one binds to its
own receptor and directs a unique pattern of
synthesis of specific proteins. The specificity as
to which hormone will be bound is provided
by the hormone binding domain, while that as
to which gene will be activated or repressed
is a function of the DNA binding/N-terminus
domain. Different ligands of the same nuclear
receptor have been found to induce ligand-specific
conformations of the receptor so that different
combinations of co-activators and co-repressors
may be bound in different target tissues, e.g.
selective estrogen receptor modulators (SERMs)
tamoxifen and raloxifene have differing patterns
of action on various estrogenic target organs.
Chimeric receptors have also been produced
which respond to one hormone, but produce
the effects of the other hormone.
This transduction mechanism is the slowest in its time course of action (takes hours)
because the adequate quantity of the effector protein
will have to be produced before the response
occurs. The effects also generally out last
the signal (hormone), because the majority of the
generated effector proteins have slow turnover,
and persist in the body even after the hormone
has been eliminated.
Brian Covello: Diabetes Research ProposalBrian Covello
Brian Covello's diabetes research proposal. Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion.
Essential update: FDA approves subcutaneous albiglutide for management of DM2
The FDA has approved once-weekly injectable albiglutide (Tanzeum), a glucagonlike peptide 1 (GLP-1) receptor agonist, along with diet and exercise for the treatment of type 2 diabetes.[1, 2] This agent may be used either as monotherapy or in combination with metformin, glimepiride, pioglitazone, or insulin.
Albiglutide should not be used for the following[1, 2] :
Patients with type 1 diabetes
Patients with diabetic ketoacidosis
First-line therapy in patients who can’t be managed with diet and exercise
Patients who have a personal or family history of medullary thyroid carcinoma (MTC)
Patients who have multiple endocrine neoplasia syndrome type 2
The most common adverse reactions associated with albiglutide were nausea/diarrhea and injection-site reactions.
There will be a boxed warning on albiglutide’s labeling about thyroid C-cell tumors being observed in rodent studies with this class of drugs; it is currently unknown whether albiglutide causes these tumors in humans, including MTC.[1, 2] Moreover, the FDA is also requiring a number of postmarketing studies, including a pediatric trial; an MTC case registry (≥15 y); and a cardiovascular (CV)-outcomes trial in patients with a baseline high risk of CV disease.
Signs and symptoms
Many patients with type 2 diabetes are asymptomatic. Clinical manifestations include the following:
Classic symptoms: Polyuria, polydipsia, polyphagia, and weight loss
Blurred vision
Lower-extremity paresthesias
Yeast infections (eg, balanitis in men)
See Presentation for more detail.
Diagnosis
Diagnostic criteria by the American Diabetes Association (ADA) include the following[3] :
A fasting plasma glucose (FPG) level of 126 mg/dL (7.0 mmol/L) or higher, or
A 2-hour plasma glucose level of 200 mg/dL (11.1 mmol/L) or higher during a 75-g oral glucose tolerance test (OGTT), or
A random plasma glucose of 200 mg/dL (11.1 mmol/L) or higher in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis
Whether a hemoglobin A1c (HbA1c) level of 6.5% or higher should be a primary diagnostic criterion or an optional criterion remains a point of controversy.
Indications for diabetes screening in asymptomatic adults includes the following[4, 5] :
Sustained blood pressure >135/80 mm Hg
Overweight and 1 or more other risk factors for diabetes (eg, first-degree relative with diabetes, BP >140/90 mm Hg, and HDL < 35 mg/dL and/or triglyceride level >250 mg/dL)
ADA recommends screening at age 45 years in the absence of the above criteria
See Workup for more detail.
Different Therapeutic Aspects of Peroxisomes Proliferator-Activated ReceptorsAI Publications
Peroxisome proliferator-activated receptors (PPARs) was discovered in 1990 belong to the super family of steroid hormone receptors. Three subtypes of PPAR which have been identified so far- PPARα, PPARβ/δ, and PPARγ. Human peroxisome proliferator-activated receptors (hPPARs) were initially recognized as therapeutic targets for the development of drugs to treat metabolic disorders, such as diabetes and dyslipidemia but now they have been used in energy burning, dyslipidemia, diabetes, inflammation, Hepatic steatosis, liver cancer, diabetic neuropathy, atherosclerosis also. These are included in management of NIDDM, macrophage differentiation, adipose differentiation , anti-cancer, inhibition of TH2 cytokine production and rheumatoid arthritis. PPARβ/δ can use to treat Huntington’s disease, fertility, dyslipidemia. The functions of a third PPAR isoform and its potential as a therapeutic target are currently under investigation.
A Thesis Submitted to the College of Medicine and the Committee of Postgraduate Studies of the University of Al-Mustansiriya in Partial Fulfillment of the Requirements for the Degree of Master of Science in Pharmacology
Blocking anti-inflammatory antibodies to histamine/serotonin receptors is a prospective method of medical management of Acute Radiation Disease and can inhibit pro inflammatory cascades and possible damage of internal organs of irradiated mammals.
Il punto sul microbiota e le malattie umane- Covegno scientifico Attività scientifica
Il microbiota e le patologie umane- Perugia 20 aprile 2018- Convegno a Perugia-
Probiotici e trattamento delle patologie umane
Microbiota intestinale e malattie infiammatorie
Giornata di studio sul microbiota e patologie umane- Esperti a confronto sul ruolo dl microbiota nelle patologie dell' apparato digerente Perugia 20 aprile 2018
Meeting sul microbiota umano 20 aprile 2018
Focus su microbiota intestinale e malattie infiammatorie ed epatiche- Probiotici: come valutare un probiotico?
These slides describe the pathophysiology and the management of patients with liver cirrhosis and portal hypertension. The slides are at the level of post-graduate students
GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages Attività scientifica
Novel therapeutic approach to intestinal inflammation by targeting GPBAR1 (TGR5) stimulates release of anti-inflammatory cytokine IL-10.
Just published in J. Immunology June 2017
Nuovo website:
www.gastroenterologia.unipg.it
disponibile da oggi per aggiornamenti, didattica, blog ed informazioni sulla sezione di gastroenterologia di Perugia
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Slide 1: Title Slide
Extrachromosomal Inheritance
Slide 2: Introduction to Extrachromosomal Inheritance
Definition: Extrachromosomal inheritance refers to the transmission of genetic material that is not found within the nucleus.
Key Components: Involves genes located in mitochondria, chloroplasts, and plasmids.
Slide 3: Mitochondrial Inheritance
Mitochondria: Organelles responsible for energy production.
Mitochondrial DNA (mtDNA): Circular DNA molecule found in mitochondria.
Inheritance Pattern: Maternally inherited, meaning it is passed from mothers to all their offspring.
Diseases: Examples include Leber’s hereditary optic neuropathy (LHON) and mitochondrial myopathy.
Slide 4: Chloroplast Inheritance
Chloroplasts: Organelles responsible for photosynthesis in plants.
Chloroplast DNA (cpDNA): Circular DNA molecule found in chloroplasts.
Inheritance Pattern: Often maternally inherited in most plants, but can vary in some species.
Examples: Variegation in plants, where leaf color patterns are determined by chloroplast DNA.
Slide 5: Plasmid Inheritance
Plasmids: Small, circular DNA molecules found in bacteria and some eukaryotes.
Features: Can carry antibiotic resistance genes and can be transferred between cells through processes like conjugation.
Significance: Important in biotechnology for gene cloning and genetic engineering.
Slide 6: Mechanisms of Extrachromosomal Inheritance
Non-Mendelian Patterns: Do not follow Mendel’s laws of inheritance.
Cytoplasmic Segregation: During cell division, organelles like mitochondria and chloroplasts are randomly distributed to daughter cells.
Heteroplasmy: Presence of more than one type of organellar genome within a cell, leading to variation in expression.
Slide 7: Examples of Extrachromosomal Inheritance
Four O’clock Plant (Mirabilis jalapa): Shows variegated leaves due to different cpDNA in leaf cells.
Petite Mutants in Yeast: Result from mutations in mitochondrial DNA affecting respiration.
Slide 8: Importance of Extrachromosomal Inheritance
Evolution: Provides insight into the evolution of eukaryotic cells.
Medicine: Understanding mitochondrial inheritance helps in diagnosing and treating mitochondrial diseases.
Agriculture: Chloroplast inheritance can be used in plant breeding and genetic modification.
Slide 9: Recent Research and Advances
Gene Editing: Techniques like CRISPR-Cas9 are being used to edit mitochondrial and chloroplast DNA.
Therapies: Development of mitochondrial replacement therapy (MRT) for preventing mitochondrial diseases.
Slide 10: Conclusion
Summary: Extrachromosomal inheritance involves the transmission of genetic material outside the nucleus and plays a crucial role in genetics, medicine, and biotechnology.
Future Directions: Continued research and technological advancements hold promise for new treatments and applications.
Slide 11: Questions and Discussion
Invite Audience: Open the floor for any questions or further discussion on the topic.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
This presentation explores a brief idea about the structural and functional attributes of nucleotides, the structure and function of genetic materials along with the impact of UV rays and pH upon them.
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Bile acid activated receptors
1. RUSSIAN ACADEMY OF SCIENCES
Institute of Macromolecular Compounds
St. Petersburg
PROF. STEFANO FIORUCCI
SECTION OF GASTROENTEROLOGY
DEPARTMENT OF SURGERY AND BIOMEDICAL SCIENCES,
UNIVERSITY OF PERUGIA MEDICAL SCHOOL
BILE ACID ACTIVATED RECEPTORS: TALE OF A MULTITASKING
FAMILY
Nuclear receptors (NRs) are a large family of ligand-activated transcription
factors (Human NR superfamily include 48 members) which control numerous
metabolic pathways and processes in various organs, ranging from
proliferation to apoptosis, differentiation and energy homeostasis. Nuclear
receptors as valuable potential targets for the development of therapeutic
agents against a number of pathological conditions and diseases. Bile acids,
are the end-products of cholestrol metabolism synthesized in the liver and
secreted in the gastrointestinal tract where they undergoes a transformation
by the intestinal microbiota. In addition to their role in regulating lipid and
cholesterol absorption in the small intestinal, bile acids area signaling
molecules acting on wide range of receptors collectively known as Bile acid
activated receptors (BARs). This family includes NR such as The farnesoid
X receptor (FXR), the Vitamin D receptor (VDR), the pregnane-x-receptor
(PXR) among others and G-protein coupled receptors such as GPBAR1
(TGR5). FXR is a bile sensor that acts in coordination with other nuclear
receptors to regulate essential steps in bile acid uptake, metabolism and
excretion. FXR shares the general architecture of other NR receptors acting
as an heterodimer with RXR (retinoid-x-receptor). In addition, FXR is
involved in lipid and glucose homeostasis. FXR ligands endowed with
agonistic activity are under development for the treatment of metabolic
disorders linked to insulin resistance. GPBAR1 is a receptor regulating
energy expenditure and has relevance in the treatment of insulin resistance
and diabetes along with inflammation and immune dysfunction.
Objectives
- To describe cholesterol/bile acid metabolism and receptors
- Biology of BAR
- Medicinal chemistry of FXR and GPBAR1